Starpharma Holdings Limited (FRA:PQ6)

Market Cap	212.03M +600.7%
Revenue (ttm)	7.67M +116.5%
Net Income	-4.52M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	288.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.4360
Previous Close	0.4360
Day's Range	0.4360 - 0.4360
52-Week Range	0.0470 - 0.5200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 1, 2026

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhance...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 40
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PQ6

Financial Performance

In fiscal year 2026, Starpharma Holdings's revenue was 12.67 million, an increase of 116.55% compared to the previous year's 5.85 million. Losses were -7.47 million, -25.28% less than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error